Cargando…
Nuclear medicine imaging and therapy of neuroendocrine tumours
Radiolabelled peptides are used for specific targeting of receptors (over-)expressed by tumour cells. Dependent on the kind of labelling and the radionuclide used, these compounds may be utilised for imaging or for therapy. A concise overview is provided on basic principles of designing and developi...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
e-MED
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1805059/ https://www.ncbi.nlm.nih.gov/pubmed/17114073 http://dx.doi.org/10.1102/1470-7330.2006.9038 |
_version_ | 1782132465790353408 |
---|---|
author | Gotthardt, Martin Dijkgraaf, Ingrid Boerman, Otto C Oyen, Wim J G |
author_facet | Gotthardt, Martin Dijkgraaf, Ingrid Boerman, Otto C Oyen, Wim J G |
author_sort | Gotthardt, Martin |
collection | PubMed |
description | Radiolabelled peptides are used for specific targeting of receptors (over-)expressed by tumour cells. Dependent on the kind of labelling and the radionuclide used, these compounds may be utilised for imaging or for therapy. A concise overview is provided on basic principles of designing and developing radiopeptides for these applications. Furthermore, clinical application of these compounds for imaging and therapy is described. Advantages of the method compared to other techniques (such as the use of radiolabelled antibodies or antibody fragments) are discussed as well as pitfalls and limitations. |
format | Text |
id | pubmed-1805059 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | e-MED |
record_format | MEDLINE/PubMed |
spelling | pubmed-18050592008-10-31 Nuclear medicine imaging and therapy of neuroendocrine tumours Gotthardt, Martin Dijkgraaf, Ingrid Boerman, Otto C Oyen, Wim J G Cancer Imaging Article Radiolabelled peptides are used for specific targeting of receptors (over-)expressed by tumour cells. Dependent on the kind of labelling and the radionuclide used, these compounds may be utilised for imaging or for therapy. A concise overview is provided on basic principles of designing and developing radiopeptides for these applications. Furthermore, clinical application of these compounds for imaging and therapy is described. Advantages of the method compared to other techniques (such as the use of radiolabelled antibodies or antibody fragments) are discussed as well as pitfalls and limitations. e-MED 2006-10-31 /pmc/articles/PMC1805059/ /pubmed/17114073 http://dx.doi.org/10.1102/1470-7330.2006.9038 Text en Copyright © 2006 International Cancer Imaging Society |
spellingShingle | Article Gotthardt, Martin Dijkgraaf, Ingrid Boerman, Otto C Oyen, Wim J G Nuclear medicine imaging and therapy of neuroendocrine tumours |
title | Nuclear medicine imaging and therapy of neuroendocrine tumours |
title_full | Nuclear medicine imaging and therapy of neuroendocrine tumours |
title_fullStr | Nuclear medicine imaging and therapy of neuroendocrine tumours |
title_full_unstemmed | Nuclear medicine imaging and therapy of neuroendocrine tumours |
title_short | Nuclear medicine imaging and therapy of neuroendocrine tumours |
title_sort | nuclear medicine imaging and therapy of neuroendocrine tumours |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1805059/ https://www.ncbi.nlm.nih.gov/pubmed/17114073 http://dx.doi.org/10.1102/1470-7330.2006.9038 |
work_keys_str_mv | AT gotthardtmartin nuclearmedicineimagingandtherapyofneuroendocrinetumours AT dijkgraafingrid nuclearmedicineimagingandtherapyofneuroendocrinetumours AT boermanottoc nuclearmedicineimagingandtherapyofneuroendocrinetumours AT oyenwimjg nuclearmedicineimagingandtherapyofneuroendocrinetumours |